spacer
home > pmps > autumn 2017 > convenience, compliance and cartons
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Convenience, Compliance and Cartons

PMPS: Patient adherence is a current hot topic. Why is it of such interest to the industry?

Dr Daniel Keesman: Pharmaceutical companies lose hundreds of billions of dollars every year due to the fact that patients do not stick to their medication plan or do not take the prescribed medicine. Not only do they want to prove that their drugs are effective, pharma companies have an interest in improving adherence and compliance.

In your experience, what have been the biggest obstacles to adherence in pharma packaging over the past 10 years?

Primary packaging has improved in recent years, for instance, by inventing auto injection devices and pens to prevent the patient from seeing the scary needle. Secondary packaging is, unfortunately, very often thrown away, as it only serves as a transportation and value protection. Further, the leaflets are not put into the folding carton again after first use as nobody is able to fold them back to the same size it was when delivered.

Technical devices supporting adherence that could be attached to the packaging – such as displays or near-field communication chips that can be connected to smartphones – only make sense when the drug itself is worth having a packaging that costs 5-20 times more than without such a device.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Daniel Keesman, son of a German mother and a Dutch father, was born in New York, US, and is therefore still an American. For nearly 10 years, he has been part of the executive board of the quality-oriented pharmaceutical packaging manufacturer. He entered August Faller Group as Managing Partner in 2009 and is responsible for the development of national and international markets.
spacer
Dr Daniel Keesman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement